Table 2 |
|||
|
Clinical and parasitological efficacy |
|||
| PCR-corrected failure rates |
A/L |
Quinine |
A/P |
|
|
|||
| Clinical failure rate day 7 |
0/30 |
0/35 |
0/32 |
| Parasitological failure rate day 7 |
0/30 |
0/35 |
0/32 |
| Intention to treat failure rate* day 7 |
0/30 |
1/35 (~3%) |
0/32 |
| Clinical failure rate day 28 |
0/30 |
3/35 (~9%) |
1/32 (~3%) |
| Parasitological failure rate day 28 |
0/30 |
3/35 (~9%) |
2/32 (~6%) |
| Intention to treat failure rate* day 28 |
0/30 |
7/35 (~20%) |
4/32 (~13%) |
|
|
|||
| Recurrent parasitaemia |
|||
|
|
|||
| Number of patients with recrudescence** (day) |
1 (70) |
4 (24, 28, 28, 40***) |
2 (28, 28) |
| Number of patients with new infection** (day) |
1 (73) |
4 (34, 40, 40***, 65) |
1 (80) |
| Number of patients with P. vivax infection (day) |
2 (28, 28) |
5 (22, 25, 27, 28, 28) |
2 (28, 28) |
|
|
|||
| Gametocytaemia |
|||
|
|
|||
| Number of patients on day 0 |
1 |
3 |
1 |
| Number of patients on day 7 |
2 |
10 |
16 |
| Number of patients on day 28 |
0 |
2 |
0 |
|
|
|||
|
* lost to follow-up included **P. falciparum: Genotyping by PCR and RFLP patterns of the MSP-1 and MSP-2 gene *** One sample showed two different clones on day 40, one of them corresponded to the clone on day 0. |
|||
|
Gürkov et al. Malaria Journal 2008 7:179 doi:10.1186/1475-2875-7-179 |
|||
